BioSpace News Archive

ZEISS presents new enhanced software technology

ZEISS ZEN Connect provides information from all dimensions of a sample

September 19, 2018
·
1 min read
Deals

NOXXON ANNOUNCES LISTING OF CONVERTIBLE BONDS AND ADDITIONAL INVESTMENT

NOXXON Pharma N.V. announced today that the previously disclosed convertible bonds (see press releases of June 15 and August 1, 2018) have been listed on the Euronext Access market in Paris as notes convertible into NOXXON shares

September 19, 2018
·
4 min read
Persons with Alzheimer’s disease are more often hospitalized after initiating antibiotic use

Persons with Alzheimer’s disease (AD) are more often hospitalized after antibiotic initiation than people without AD, a new study from the University of Eastern Finland shows.

September 19, 2018
·
1 min read
Business

MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics

LEO Pharma A/S and MorphoSys AG today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics.

September 19, 2018
·
6 min read
Business

ASHBURN TEEN AWARDED $25,000 FOR DEVELOPING NEW THERAPEUTIC FOR HEART DISEASE

Marissa Sumathipalato be Named a 2018 Davidson Fellow

September 19, 2018
·
3 min read
Bio NC

Rho Ranks First for Extra-Large Company by Triangle Business Journal Best Places to Work

CRO recognized for its company culture and flexible work environment

September 19, 2018
·
1 min read
Business

ImCheck Therapeutics Appoints Prof. René Hoet, PhD, as Chief Scientific Officer

René Hoet brings over 20 years of experience as a leader in antibody discovery and development

September 19, 2018
·
2 min read
Drug Development

AstraZeneca’s Asthma Drug Looks Good in Multiple Late-Stage Trials

AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.

September 19, 2018
·
3 min read
·
Mark Terry
Drug Development

Galera Therapeutics Nabs $150 Million to Drive Lead Therapeutic Into Phase III

Privately-held Galera Therapeutics, Inc. secured $150 million in a Series C funding round that will be used to drive its experimental head and neck cancer treatment GC4419 into Phase III trials, as well as support pre-commercialization activities.

September 19, 2018
·
2 min read
·
Alex Keown
Policy

FDA Requests Another Trial for Pharming’s Ruconest Label Expansion

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), basically a rejection, to Netherlands-based Pharming Group for its supplemental Biologics License Application (sBLA) for Ruconest.

September 19, 2018
·
2 min read
·
Mark Terry